Abstract
The in vivo activities of imipenem, meropenem, and cefepime were studied in a model of rat pneumonia caused by a plasmid-mediated AmpC beta-lactamase ACT-1-producing Klebsiella pneumoniae strain (K. pneumoniae strain 12) and a derivative porin-deficient mutant (K. pneumoniae strain 12dp). No differences between these activities were seen with K. pneumoniae 12. Only meropenem showed an activity slightly better than that of imipenem with K. pneumoniae 12dp.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Proteins / genetics
-
Bacterial Proteins / metabolism*
-
Cefepime
-
Cephalosporins / pharmacokinetics
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use
-
Colony Count, Microbial
-
Imipenem / pharmacokinetics
-
Imipenem / pharmacology
-
Imipenem / therapeutic use
-
In Vitro Techniques
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology
-
Klebsiella pneumoniae / genetics
-
Male
-
Meropenem
-
Microbial Sensitivity Tests
-
Plasmids
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Porins / deficiency*
-
Porins / genetics
-
Rats
-
Rats, Wistar
-
Thienamycins / pharmacokinetics
-
Thienamycins / pharmacology
-
Thienamycins / therapeutic use
-
Treatment Outcome
-
beta-Lactamases / genetics
-
beta-Lactamases / metabolism*
-
beta-Lactams / pharmacokinetics
-
beta-Lactams / pharmacology
-
beta-Lactams / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Cephalosporins
-
Porins
-
Thienamycins
-
beta-Lactams
-
Imipenem
-
Cefepime
-
AmpC beta-lactamases
-
beta-Lactamases
-
Meropenem